TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

TScan Therapeutics, Inc. (NASDAQ:TCRX) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,900,000 shares, a decline of 14.8% from the February 28th total of 2,230,000 shares. Approximately 4.4% of the company’s shares are sold short. Based on an average trading volume of 433,800 shares, the days-to-cover ratio is presently 4.4 days.

Analysts Set New Price Targets

TCRX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research note on Thursday, March 6th. Barclays reduced their target price on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Wednesday, March 5th. Morgan Stanley reissued an “overweight” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, Needham & Company LLC decreased their price objective on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $9.33.

Institutional Trading of TScan Therapeutics

Large investors have recently added to or reduced their stakes in the business. Stifel Financial Corp boosted its holdings in TScan Therapeutics by 3.9% in the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after purchasing an additional 3,733 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after buying an additional 4,852 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after acquiring an additional 5,694 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of TScan Therapeutics by 5.2% in the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Finally, Woodline Partners LP grew its holdings in TScan Therapeutics by 6.7% during the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after purchasing an additional 7,282 shares during the last quarter. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Trading Up 2.2 %

NASDAQ TCRX opened at $1.38 on Tuesday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics has a 1-year low of $1.28 and a 1-year high of $9.69. The firm’s fifty day simple moving average is $2.02 and its 200-day simple moving average is $3.53. The company has a market capitalization of $78.10 million, a PE ratio of -1.30 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $1.43 million. As a group, sell-side analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.